Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 1/2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1

Conditions

Neoplasms 3Respiratory Tract Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Cancer 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × efatutazone × Clear all
NCT01199068 2021-05-13

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Daiichi Sankyo

Phase 1 Completed
15 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

NCT00408434 2020-10-19

Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

Daiichi Sankyo

Phase 1 Completed
32 enrolled 17 charts
Tumor-Agnostic

Neoplasms

NCT00881569 2020-09-28

Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017

Daiichi Sankyo

Phase 1 Completed
2 enrolled 9 charts

Advanced Cancer

NCT01199055 2020-07-07

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Daiichi Sankyo

Phase 1 Completed
16 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡